durvalumab,Oleclumab
Astrazeneca
['tnbc', 'imfinzi', 'breast', 'oleclumab', 'durva']
targeted combo flops as first-line treatment in #triplenegativebreastcancer (#tnbc) no clinical benefit boost w/ #anticd73oleclumab added to #durvalumab (#imfinzi) and chemo #esmo
Associate Professor Radiology in Breast Imaging | Alum @MayoClinicSOM @HarvardChanSPH | #BreastCancer #AI  #PublicHealth | Tweets?Endorsement